1
|
Kennedy AE, Laamanen CA, Ross MS, Vohra R, Boreham DR, Scott JA, Ross GM. Nerve growth factor inhibitor with novel-binding domain demonstrates nanomolar efficacy in both cell-based and cell-free assay systems. Pharmacol Res Perspect 2018; 5. [PMID: 28971611 PMCID: PMC5625151 DOI: 10.1002/prp2.339] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2017] [Revised: 03/30/2017] [Accepted: 04/20/2017] [Indexed: 12/15/2022] Open
Abstract
Nerve growth factor (NGF), a member of the neurotrophin family, is known to regulate the development and survival of a select population of neurons through the binding and activation of the TrkA receptor. Elevated levels of NGF have been associated with painful pathologies such as diabetic neuropathy and fibromyalgia. However, completely inhibiting the NGF signal could hold significant side effects, such as those observed in a genetic condition called congenital insensitivity to pain and anhidrosis (CIPA). Previous methods of screening for NGF‐inhibitors used labeling techniques which have the potential to alter molecular interactions. SPR spectroscopy and NGF‐dependent cellular assays were utilized to identify a novel NGF‐inhibitor, BVNP‐0197 (IC50 = 90 nmol/L), the first NGF‐inhibitor described with a high nanomolar NGF inhibition efficiency. The present study utilizes molecular modeling flexible docking to identify a novel binding domain in the loop II/IV cleft of NGF.
Collapse
Affiliation(s)
- Allison E Kennedy
- Northern Ontario School of Medicine, Sudbury, Ontario, Canada.,Laurentian University, Biomolecular Sciences Program, Sudbury, Ontario, Canada
| | - Corey A Laamanen
- Northern Ontario School of Medicine, Sudbury, Ontario, Canada.,Laurentian University, Bharti School of Engineering, Sudbury, Ontario, Canada
| | - Mitchell S Ross
- Northern Ontario School of Medicine, Sudbury, Ontario, Canada
| | - Rahul Vohra
- Northern Ontario School of Medicine, Sudbury, Ontario, Canada.,Sussex Research Laboratories Inc., Ottawa, Ontario, Canada
| | | | - John A Scott
- Northern Ontario School of Medicine, Sudbury, Ontario, Canada.,Laurentian University, Bharti School of Engineering, Sudbury, Ontario, Canada
| | - Gregory M Ross
- Northern Ontario School of Medicine, Sudbury, Ontario, Canada
| |
Collapse
|
3
|
Andreasson ASI, Karamanou DM, Gillespie CS, Özalp F, Butt T, Hill P, Jiwa K, Walden HR, Green NJ, Borthwick LA, Clark SC, Pauli H, Gould KF, Corris PA, Ali S, Dark JH, Fisher AJ. Profiling inflammation and tissue injury markers in perfusate and bronchoalveolar lavage fluid during human ex vivo lung perfusion. Eur J Cardiothorac Surg 2017; 51:577-586. [PMID: 28082471 PMCID: PMC5400024 DOI: 10.1093/ejcts/ezw358] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/21/2016] [Accepted: 08/12/2016] [Indexed: 12/13/2022] Open
Abstract
OBJECTIVES: Availability of donor lungs suitable for transplant falls short of current demand and contributes to waiting list mortality. Ex vivo lung perfusion (EVLP) offers the opportunity to objectively assess and recondition organs unsuitable for immediate transplant. Identifying robust biomarkers that can stratify donor lungs during EVLP to use or non-use or for specific interventions could further improve its clinical impact. METHODS: In this pilot study, 16 consecutive donor lungs unsuitable for immediate transplant were assessed by EVLP. Key inflammatory mediators and tissue injury markers were measured in serial perfusate samples collected hourly and in bronchoalveolar lavage fluid (BALF) collected before and after EVLP. Levels were compared between donor lungs that met criteria for transplant and those that did not. RESULTS: Seven of the 16 donor lungs (44%) improved during EVLP and were transplanted with uniformly good outcomes. Tissue and vascular injury markers lactate dehydrogenase, HMGB-1 and Syndecan-1 were significantly lower in perfusate from transplanted lungs. A model combining IL-1β and IL-8 concentrations in perfusate could predict final EVLP outcome after 2 h assessment. In addition, perfusate IL-1β concentrations showed an inverse correlation to recipient oxygenation 24 h post-transplant. CONCLUSIONS: This study confirms the feasibility of using inflammation and tissue injury markers in perfusate and BALF to identify donor lungs most likely to improve for successful transplant during clinical EVLP. These results support examining this issue in a larger study.
Collapse
Affiliation(s)
- Anders S I Andreasson
- Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.,Cardiopulmonary Transplantation, Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, UK
| | - Danai M Karamanou
- Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
| | - Colin S Gillespie
- School of Mathematics & Statistics, Newcastle University, Newcastle upon Tyne, UK
| | - Faruk Özalp
- Cardiopulmonary Transplantation, Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, UK
| | - Tanveer Butt
- Cardiopulmonary Transplantation, Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, UK
| | - Paul Hill
- Cardiopulmonary Transplantation, Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, UK
| | - Kasim Jiwa
- Cardiopulmonary Transplantation, Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, UK
| | - Hannah R Walden
- Department of Applied Sciences, Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, UK
| | - Nicola J Green
- Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.,Cardiopulmonary Transplantation, Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, UK
| | - Lee A Borthwick
- Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
| | - Stephen C Clark
- Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.,Cardiopulmonary Transplantation, Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, UK
| | - Henning Pauli
- Cardiopulmonary Transplantation, Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, UK
| | - Kate F Gould
- Cardiopulmonary Transplantation, Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, UK
| | - Paul A Corris
- Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.,Cardiopulmonary Transplantation, Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, UK
| | - Simi Ali
- Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
| | - John H Dark
- Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.,Cardiopulmonary Transplantation, Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, UK
| | - Andrew J Fisher
- Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.,Cardiopulmonary Transplantation, Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, UK
| |
Collapse
|
4
|
Fraser S, Shih JY, Ware M, O'Connor E, Cameron MJ, Schwickart M, Zhao X, Regnstrom K. Current Trends in Ligand Binding Real-Time Measurement Technologies. AAPS JOURNAL 2017; 19:682-691. [PMID: 28321830 DOI: 10.1208/s12248-017-0067-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/10/2017] [Accepted: 02/24/2017] [Indexed: 01/01/2023]
Abstract
Numerous advances in ligand binding assay (LBA) real-time measurement technologies have been made within the last several years, ranging from the development of novel platforms to drive technology expansion to the adaptation of existing platforms to optimize performance and throughput. In this review, we have chosen to focus on technologies that provide increased value to two distinct segments of the LBA community. First, experimentally, by measuring real-time binding events, these technologies provide data that can be used to interrogate receptor/ligand binding interactions. While overall the platforms are not new, they have made significant advances in throughput, multiplexing, and/or sensitivity. Second, clinically, these point-of-care (POC) technologies provide instantaneous information which facilitates rapid treatment decisions.
Collapse
Affiliation(s)
| | - Judy Y Shih
- Amgen Inc., One Amgen Center Drive, Thousand Oaks, California, 91320, USA
| | - Mark Ware
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, Pennsylvania, 19477, USA
| | - Edward O'Connor
- AegisBioconsult, 78 Marbern Dr., Suffield, Connecticut, 06078, USA
| | - Mark J Cameron
- Lumigen, 22900 8 Mile Road, Southfield, Michigan, 48033, USA
| | - Martin Schwickart
- MedImmune, 319 N. Bernardo Ave, Mountain View, California, 94043, USA
| | - Xuemei Zhao
- Merck Research Laboratories, Rahway, New Jersey, 07065, USA
| | - Karin Regnstrom
- Boehringer Ingelheim, 6701 Kaiser Drive, Fremont, California, 94555, USA
| |
Collapse
|